

Lesson 3 Quiz

Keep track of your answers by clicking the bubbles next to your choice. At the end of the quiz, you will find an answer key so you can see how you did. Good luck!

1. How are patients monitored after they begin an advanced therapy?
 - a) **Safety and effectiveness measurement**
 - b) **Disease progress assessment by rheumatologist**
 - c) **Lab tests**
 - d) **All of the above**

2. Targeted small molecule medicines include:
 - a) **Tylenol arthritis**
 - b) **Apremilast and tofacitinib**
 - c) **Originator biologics**
 - d) **Biosimilars biologics**

3. Biologic DMARDs include:
 - a) **Originators Biologics**
 - b) **Leflunomide**
 - c) **Biosimilars biologics**
 - d) **a) and c)**

4. Health Canada considers well-controlled transitions from an originator biologic to its biosimilar biologic in an approved indication to be acceptable. Please refer to “Transitioning from an originator biologic to a biosimilar biologic” section in Lesson 3.
True False

5. To fill an advance therapy prescription, the patient _____.
- a) **Receives a written prescription from a rheumatologist**
 - b) **Contacts the patient support program for their medication**
 - c) **Obtains prescription from a pharmacy or infusion clinic**
 - d) **All of the above**
6. To be eligible for reimbursement coverage, most public and private drug plans require all advanced therapies to be prescribed by a rheumatologist and patients must meet certain criteria to ensure that the advanced therapy prescription follows best clinical practice guidelines.
- True False**

Answer Key

You can check your answers here.
Each question is worth one point.
**Record your score by filling
out the box on the bottom right.**

- 1. d) All of the above
- 2. b) Apremilast and...
- 3. d) a) and c)
- 4. True
- 5. d) All of the above
- 6. True

Score
/6